YourDNA and DNA ID Announce Partnership to Further Improve Genetic Research

August 28, 2019 (PRLEAP.COM) Business News
YourDNA and DNA ID today announced a new partnership designed to connect rare disease patients to genetic researchers in a safe and secure way.

By forming this partnership, YourDNA and DNA ID are teaming up to make it easier for patients with rare genetic diseases to come together to form communities where they can find support, as well as a chance to further medical research for their condition.

  • YourDNA is an agnostic media platform helping raise awareness and understanding about advances in genomics. YourDNA community stakeholders range from genetic counselors to healthcare providers, clinicians, companies, charities, researchers and more.
  • DNA ID helps medical research accelerate treatments by creating an open access data platform that puts control back in the patient's hands. The DNA ID marketplace empowers patients to have a voice in new medical research.

  • There are over 7,000 rare diseases recognized by the scientific community. Since each one affects less than 200,000 people by definition, finding enough data for quality research is a significant stumbling block to finding a cure, or even a treatment plan.

    DNA ID allows patients to opt-in to research studies where they can anonymously share their health information, including DNA results. Individuals are able to participate and contribute to advancements in medical research, as well as receive fair compensation for their participation.

    By allowing patients to share their DNA testing results anonymously, researchers are then able obtain data from around the world. This allows them to study more cases and with larger data samples thereby improving the reliability of the results.

    DNA ID founder, Craig Calderone, has this to say about the new alliance, "With the right tools and partnerships in place like and DNA ID, we can empower rare disease patients along their entire journey. I'm really excited to see what a collective effort between our organizations can do to help accelerate research and treatments for the rare disease community."

    For patients and caregivers, this scenario is a win-win. First, they get access to a community of people who are faced with similar conditions. A sense of belonging and the knowledge they are not alone can make a world of difference to emotional well-being. Moreover, patients can also feel good about taking a more active role in the search for a cure and better treatment plans.

    YourDNA hopes this partnership is another step forward in the fight to improve outcomes for patients with rare genetic disorders.

    For its part, YourDNA is fast building communities of patients and practitioners who are affected by inherited rare diseases, as well as providing agnostic information to help the broader public better understand advances in DNA testing and genomic science.

    The partnership with DNA ID will help connect YourDNA's web visitors and app users with a direct opportunity to explore the DNA ID platform.

    The announcement comes on the heels of further efforts to make inroads in the rare disease community. A partnership with Cure Rare Disease was announced in June of this year.

    YourDNA rests at the intersection of two colliding trends, healthcare becoming more searchable by and accessible to the mass market, and genomic science beginning to deliver on the promise of precision medicine to future generations. YourDNA is a resource for consumers, patients and practitioners to uncover the most pressing and up-to-date answers on genomic advancements. The company is a subsidiary of Aspect Health Inc. and is based in San Diego, California.

    Learn more at

    DNA ID
    DNA ID, based in New York City, is actively building a community focused on realizing precision medicine in rare diseases through technology. Our goal is the acceleration of therapeutic development by giving researchers a more complete picture of real-world evidence. DNA ID simplifies data collection, data analysis and data sharing through a mobile-based patient registry platform, in turn, creating a privacy-centric research matching platform for feasibility and observational studies.

    Learn more at

    Share Article